Origene Technologies

OriGene Technologies, Inc., is a gene centric life sciences company dedicated to the support of academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product lines include the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB™), 140,000 highly validated human tissues, and protein microarray products and services. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from the Company's tissue collection. Through its recent acquisition of Blue Heron Biotechnology, a pioneer in the gene synthesis business, OriGene provides a whole product solution for customers within the life science community. On March 12, 2012, OriGene Technologies, Inc. announces the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market.
Type
Private
HQ
Rockville, US
Founded
1996
Employees
88 (est)+2%
Origene Technologies was founded in 1996 and is headquartered in Rockville, US

Origene Technologies Locations

Rockville, US
Beijing, CN
Herford, DE

Origene Technologies Metrics

Origene Technologies Summary

Founding Date

1996

Total Funding

$69.6 M

Latest funding size

$17.1 M

Time since last funding

over 1 year

Investors

Origene Technologies's latest funding round of $17.1 M was in June 2015. In total, Origene Technologies has raised $69.6 M.
9% of current employees of Origene Technologies are female and 91% are male.

Origene Technologies Online Presence

Origene Technologies News

Origene Technologies Company Life

You may also be interested in